Anagrelide for the treatment of thrombocythaemia in daily clinical practice: a post-marketing observational survey on efficacy and safety performed in Germany.

Author(s): Schmitz S, Stauch M, Schlag R

Affiliation(s): Gemeinschaftspraxis fur Hamatologie und Onkologie, Koln, Germany. info@onkologie-koeln.de

Publication date & source: 2010, Onkologie., 33(1-2):39-44. Epub 2010 Jan 18.

Publication type: Multicenter Study; Research Support, Non-U.S. Gov't

BACKGROUND: Myeloproliferative diseases - in particular essential thrombocythaemia (ET) - may be associated with increases in platelet count which put patients at risk of life-threatening complications such as thromboses and severe bleedings. PATIENTS AND METHODS: This multicentre post-marketing observational survey was conducted to assess the efficacy and safety of anagrelide under daily practice conditions in at-risk patients with ET who received anagrelide for the first time. RESULTS: 198 patients (median age of 64 years, range 19-88 years) were included, 61.1% of the patients were women. The mean observation time was 6.2 +/- 1.7 months. Treatment with anagrelide lowered the platelet counts by a median of 316 x 10(9)/l from a median of 797 x 10(9)/l at the beginning of the observation to 470 x 10(9)/l at the last observation (log rank test, p < 0.001). Disease-related complications were reduced during treatment compared to 6 months prior to treatment (transient ischaemic attacks from 1.5 to 0.5%; thromboses from 7.6 to 0%). The number of bleedings remained the same at 1.5%. Adverse events were documented in 46 patients (23.2%). All observed adverse events were similar to those previously reported in clinical studies. CONCLUSION: Anagrelide was effective in lowering the platelet count and was also well tolerated when used in daily clinical practice. (c) 2010 S. Karger AG, Basel.